What is Joint Academy?
Joint Academy, operating under the umbrella of Arthro, is a digital health company dedicated to providing a scientifically-backed, long-term treatment for osteoarthritis. Developed in close collaboration with leading osteoarthritis researchers, orthopedic specialists, and experienced physiotherapists, the company's treatment adheres to both national and international guidelines. Arthro maintains the same rigorous standards as traditional healthcare providers regarding health journals and the protection of personal data. The company has published peer-reviewed studies to validate the efficacy of its treatment, positioning itself as a key player in evidence-based digital therapeutics for chronic conditions.
How much funding has Joint Academy raised?
Joint Academy has raised a total of $30M across 2 funding rounds:
Series A
$7M
Series B
$23M
Series A (2018): $7M, investors not publicly disclosed
Series B (2020): $23M led by Kinnevik
Key Investors in Joint Academy
Kinnevik
Kinnevik is an industry-focused investment company with an entrepreneurial spirit, dedicated to building digital consumer businesses. They partner with founders to create and lead fast-growing companies, aiming to deliver both shareholder and social value.
What's next for Joint Academy?
The recent major strategic investment signifies Joint Academy's transition into a scaling phase, likely focused on expanding its digital platform's reach and enhancing its service offerings. This capital infusion will enable the company to further its mission of providing effective, accessible osteoarthritis management solutions globally. Future growth will likely involve deeper integration with healthcare systems and continued research to refine its treatment protocols, solidifying its position as a leader in digital musculoskeletal health.
See full Joint Academy company page
